Atezolizumab (Tecentriq) 1200mg/20ml for 1 vial

Tecentriq (atezolizumab) is a monoclonal antibody used in cancer immunotherapy. It comes in a concentration of 1200mg/20ml per vial and is administered via intravenous infusion. Atezolizumab is designed to help the immune system recognize and combat cancer cells.

How It Works

Atezolizumab works by targeting and inhibiting the programmed death-ligand 1 (PD-L1) protein, which is often overexpressed on the surface of tumor cells and immune cells within the tumor microenvironment. PD-L1 binds to the PD-1 receptor on T-cells, effectively turning off the T-cell’s ability to attack the tumor. By blocking this interaction, atezolizumab reactivates T-cells, enabling them to detect and destroy cancer cells.

Indications

• Non-small cell lung cancer (NSCLC)
• Small cell lung cancer (SCLC)
• Urothelial carcinoma (a type of bladder cancer)
• Triple-negative breast cancer (TNBC)
• Hepatocellular carcinoma (HCC, a type of liver cancer)
• Renal cell carcinoma (RCC, a type of kidney cancer)

Contraindications

• Severe hypersensitivity to atezolizumab or any of its components
• Patients with active autoimmune diseases requiring systemic immunosuppressive treatment
• Patients with active infections requiring systemic therapy
• Pregnancy and breastfeeding

Side Effects

• Fatigue
• Decreased appetite
• Nausea
• Cough
• Dyspnea (shortness of breath)
• Constipation
• Musculoskeletal pain
• Immune-related adverse effects (e.g., pneumonitis, hepatitis, colitis, endocrinopathies)

Price in Different Countries

Top 5 Global Brands

• Tecentriq (Roche): The original brand of atezolizumab, widely used in many countries for various types of cancer treatment.
• Keytruda (Merck & Co.): Another leading immunotherapy drug, though it targets PD-1 instead of PD-L1.
• Opdivo (Bristol-Myers Squibb): Similar to Keytruda, this drug targets the PD-1 receptor and is used for multiple cancer types.
• Imfinzi (AstraZeneca): This drug targets PD-L1, like Tecentriq, and is used for similar indications.
• Bavencio (EMD Serono/Pfizer): Another PD-L1 inhibitor used in cancer immunotherapy.